Used in targeted cancer therapies, particularly for renal cell carcinoma and ovarian cancer, due to its specific binding to CDH6 (K-cadherin), a protein overexpressed in these tumor types. It serves as a key component in antibody-drug conjugates (ADCs), where it delivers cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. Its high specificity enhances therapeutic efficacy and supports ongoing clinical development in oncology.